Indications -- Lupus/Nephritis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Lupus/Nephritis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: michael_f_murphy who wrote (42)	6/25/2002 10:54:30 AM
From: keokalani'nui	Read Replies (1) of 95

Active Biotech has Selected a New Candidate Drug for the Treatment of Lupus LUND, Sweden--(BUSINESS WIRE)--June 25, 2002--Active Biotech has selected a Candidate Drug, ABR-215757, within the SLE project for further development into clinical phase. The Candidate Drug ABR-215757 is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease with very few available treatments today. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide. The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next